Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial
- Mark C. Petrie
- , Jacob A. Udell
- , Stefan D. Anker
- , Josephine Harrington
- , W. Schuyler Jones
- , Michaela Mattheus
- , Tomasz Gasior
- , Peter van der Meer
- , Offer Amir
- , M. Cecilia Bahit
- , Johann Bauersachs
- , Antoni Bayes-Genis
- , Vijay K. Chopra
- , James L. Januzzi
- , Renato D. Lopes
- , Piotr Ponikowski
- , Xavier Rossello
- , Morten Schou
- , Shelley Zieroth
- , Martina Brueckmann
- Glasgow Cardiovascular Research Centre
- Toronto General Hospital
- Berlin Institute of Health
- Duke University
- Boehringer Ingelheim GmbH
- WSB University
- University of Groningen
- Hadassah University Medical Centre
- Fundación INECO
- Hannover Medical School
- Generalitat de Catalunya
- Max Super Speciality Hospital, Delhi
- Harvard Clinical Research Institute
- Wrocław Medical University
- Hospital Universitario Son Espases
- University of Copenhagen
- University of Manitoba
- Heidelberg University
- Icahn School of Medicine at Mount Sinai
- Baylor Scott & White Health
Research output: Contribution to journal › Article › peer-review
3
Scopus
citations